| Primary |
| Lymphoma |
12.8% |
| Diffuse Large B-cell Lymphoma |
10.5% |
| Infantile Genetic Agranulocytosis |
8.1% |
| Pneumonia |
8.1% |
| Gastric Ulcer |
5.8% |
| Hyperaldosteronism |
5.8% |
| Insomnia |
5.8% |
| Acute Myeloid Leukaemia |
4.7% |
| Breast Cancer |
4.7% |
| Constipation |
4.7% |
| Hypertension |
4.7% |
| Bone Sarcoma |
3.5% |
| Neutropenia |
3.5% |
| Small Cell Lung Cancer Limited Stage |
3.5% |
| Antifungal Prophylaxis |
2.3% |
| Chemotherapy |
2.3% |
| Hyperuricaemia |
2.3% |
| Leukopenia |
2.3% |
| Myelodysplastic Syndrome |
2.3% |
| Neutrophil Count Decreased |
2.3% |
|
| Myelodysplastic Syndrome |
12.0% |
| Acute Respiratory Distress Syndrome |
8.0% |
| Anaphylactoid Reaction |
8.0% |
| Interstitial Lung Disease |
8.0% |
| Acute Myeloid Leukaemia |
4.0% |
| Anaphylactic Reaction |
4.0% |
| Anaphylactic Shock |
4.0% |
| Chest Pain |
4.0% |
| Cytokine Release Syndrome |
4.0% |
| Drug Effect Incomplete |
4.0% |
| Feeling Abnormal |
4.0% |
| Ileal Ulcer |
4.0% |
| Iritis |
4.0% |
| Myalgia |
4.0% |
| Osteonecrosis |
4.0% |
| Psoriasis |
4.0% |
| Pulmonary Fibrosis |
4.0% |
| Rash Maculo-papular |
4.0% |
| Shock |
4.0% |
| Takayasu's Arteritis |
4.0% |
|
| Secondary |
| Adult T-cell Lymphoma/leukaemia |
23.7% |
| Breast Cancer |
9.7% |
| Prophylaxis |
8.1% |
| Pneumonia |
5.9% |
| Febrile Neutropenia |
5.7% |
| Back Pain |
4.8% |
| Infection |
4.8% |
| Lung Adenocarcinoma Metastatic |
4.3% |
| Parkinson's Disease |
4.3% |
| Myelodysplastic Syndrome |
4.1% |
| Neutrophil Count Decreased |
4.1% |
| B-cell Lymphoma |
3.2% |
| Pancytopenia |
2.9% |
| Bone Sarcoma |
2.7% |
| Antibiotic Prophylaxis |
2.0% |
| Gastric Mucosal Lesion |
2.0% |
| Pneumocystis Jiroveci Pneumonia |
2.0% |
| Tumour Lysis Syndrome |
2.0% |
| Acute Myeloid Leukaemia |
1.8% |
| Deep Vein Thrombosis |
1.8% |
|
| Neutrophil Count Decreased |
15.2% |
| Weight Decreased |
12.0% |
| Pyrexia |
9.8% |
| Interstitial Lung Disease |
8.7% |
| Febrile Neutropenia |
5.4% |
| Pulmonary Fibrosis |
5.4% |
| Respiratory Failure |
5.4% |
| Bone Marrow Failure |
4.3% |
| Pulmonary Alveolar Haemorrhage |
4.3% |
| Rhabdomyolysis |
4.3% |
| Erythromelalgia |
3.3% |
| Shock |
3.3% |
| Upper Gastrointestinal Haemorrhage |
3.3% |
| Erythema Multiforme |
2.2% |
| Pulmonary Congestion |
2.2% |
| Renal Disorder |
2.2% |
| Septic Shock |
2.2% |
| Tremor |
2.2% |
| Ventricular Fibrillation |
2.2% |
| Vomiting |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
20.0% |
| Prophylaxis |
19.1% |
| Aplastic Anaemia |
7.7% |
| Drug Use For Unknown Indication |
6.6% |
| Infection Prophylaxis |
5.1% |
| Multiple Myeloma |
4.7% |
| Nutritional Support |
4.5% |
| Stem Cell Transplant |
3.5% |
| Immunosuppression |
3.1% |
| Acute Lymphocytic Leukaemia |
3.1% |
| Prophylaxis Against Graft Versus Host Disease |
3.0% |
| Blood Bilirubin Increased |
2.8% |
| Febrile Neutropenia |
2.6% |
| Hypertension |
2.5% |
| Constipation |
2.5% |
| Tuberculous Pleurisy |
2.2% |
| Antifungal Prophylaxis |
2.0% |
| Myelodysplastic Syndrome |
1.8% |
| Acute Myeloid Leukaemia |
1.7% |
| Allogenic Bone Marrow Transplantation Therapy |
1.6% |
|
| White Blood Cell Count Decreased |
26.4% |
| Sepsis |
8.3% |
| Weight Decreased |
7.6% |
| Pneumonia |
7.1% |
| Renal Impairment |
5.6% |
| Febrile Neutropenia |
4.4% |
| Stomatitis |
4.4% |
| Vomiting |
4.2% |
| Pyrexia |
4.1% |
| Platelet Count Decreased |
3.7% |
| Interstitial Lung Disease |
3.4% |
| Neutrophil Count Decreased |
3.4% |
| Liver Disorder |
2.7% |
| Shock Haemorrhagic |
2.5% |
| White Blood Cell Count Increased |
2.4% |
| Thrombocytopenia |
2.2% |
| Pneumatosis Intestinalis |
2.0% |
| Thrombotic Microangiopathy |
2.0% |
| C-reactive Protein Increased |
1.9% |
| Hepatic Function Abnormal |
1.7% |
|
